Indeed, EGFR-mutant tumors that also carry TP53 mutations (and often have higher tumor mutational burden, TMB) could be slightly more responsive to immunotherapy than EGFR-mutant/TP53-wild-type tumors, according to some reports [48]. The gene discussed is EGFR; the disease is neoplasm.